We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
StarLIMS wins FDA software deal
News

StarLIMS wins FDA software deal

StarLIMS wins FDA software deal
News

StarLIMS wins FDA software deal

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "StarLIMS wins FDA software deal"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

StarLIMS Ltd. has begun installing the company's software-based laboratory information management system (LIMS) with the US Food and Drug Administration (FDA) to enhance its testing laboratories for food and drug chemistries, devices, forensics material and microbiology samples.

The software will be used to manage complex processes and the analysis of the vast amounts of information generated by FDA laboratories. The LIMS solution will provide the needed capability to manage the analytical workflow operations in FDA’s Office of Regulatory Affairs 14 labs for approximately 825 users supporting sample accountability, data analysis, document control, report generation, and other lab operation functions.

“We’re looking forward to working on this important initiative,” said StarLIMS head Isaac Friedman. “STARLIMS has a successful track record in implementing web-based LIMS for life sciences organizations, public health laboratories and a number of federal agencies."

Isaac Friedman and his brother Chaim founded StarLIMS and took it public on the Tel Aviv Stock Exchange (TASE) and Nasdaq, before selling the company to Abbott Laboratories Inc. (NYSE: ABT).

Advertisement